We further tracked TI-CH in 49 metastases obtained at progression or autopsy from two TRACERx patients with TI-CH-positive primary tumors enrolled in PEACE (Fig S23B), the first with DNMT3A and TET2 mutations, and the second with a DNMT3A mutation. This evidence concerns the gene TET2 and cyclic hematopoiesis.